FIGURE 3.
Mechanisms of action of agents in Phase 2 of the Alzheimer's disease drug development pipeline (ClinicalTrials.gov accessed February 27, 2020)(Figure by Mike de la Flor)
Mechanisms of action of agents in Phase 2 of the Alzheimer's disease drug development pipeline (ClinicalTrials.gov accessed February 27, 2020)(Figure by Mike de la Flor)